Literature DB >> 16840332

Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death.

Subbiah Elankumaran1, Daniel Rockemann, Siba K Samal.   

Abstract

Newcastle disease virus (NDV), an avian paramyxovirus, is tumor selective and intrinsically oncolytic. Here, we present evidence that genetically modified, recombinant NDV strains are cytotoxic to human tumor cell lines of ecto-, endo-, and mesodermal origin. We show that cytotoxicity against tumor cells is due to multiple caspase-dependent pathways of apoptosis independent of interferon signaling competence. The signaling pathways of NDV-induced, cancer cell-selective apoptosis are not well understood. We demonstrate that NDV triggers apoptosis by activating the mitochondrial/intrinsic pathway and that it acts independently of the death receptor/extrinsic pathway. Caspase-8-methylated SH-SY5Y neuroblastoma cells are as sensitive to NDV as other caspase-8-competent cells. This demonstrates that NDV is likely to act primarily through the mitochondrial death pathway. NDV infection results in the loss of mitochondrial membrane potential and the subsequent release of the mitochondrial protein cytochrome c, but the second mitochondrion-derived activator of caspase (Smac/DIABLO) is not released. In addition, we describe early activation of caspase-9 and caspase-3. In contrast, cleavage of caspase-8, which is predominantly activated by the death receptor pathway, is a TNF-related, apoptosis-inducing ligand (TRAIL)-induced late event in NDV-mediated apoptosis of tumor cells. Our data, therefore, indicate that the death signal(s) generated by NDV in tumor cells ultimately converges at the mitochondria and that it acts independently of the death receptor pathway. Our cytotoxicity studies demonstrate that recombinant NDV could be developed as a cancer virotherapy agent, either alone or in combination with therapeutic transgenes. We have also shown that trackable oncolytic NDV could be developed without any reduction in oncolytic efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840332      PMCID: PMC1563725          DOI: 10.1128/JVI.00241-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  A summary of taxonomic changes recently approved by ICTV.

Authors:  M A Mayo
Journal:  Arch Virol       Date:  2002-08       Impact factor: 2.574

Review 2.  Alternative signaling pathways regulating type I interferon-induced apoptosis.

Authors:  Katja Pokrovskaja; Theocharis Panaretakis; Dan Grandér
Journal:  J Interferon Cytokine Res       Date:  2005-12       Impact factor: 2.607

3.  Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells.

Authors:  József Szeberényi; Zsolt Fábián; Beáta Töröcsik; Katalin Kiss; Laszlo K Csatary
Journal:  Am J Ther       Date:  2003 Jul-Aug       Impact factor: 2.688

4.  TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus.

Authors:  Birgit Washburn; Markus A Weigand; Anne Grosse-Wilde; Markus Janke; Heiko Stahl; Eva Rieser; Martin R Sprick; Volker Schirrmacher; Henning Walczak
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

5.  Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist.

Authors:  Zhuhui Huang; Sateesh Krishnamurthy; Aruna Panda; Siba K Samal
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

6.  Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis.

Authors:  Darren Boehning; Randen L Patterson; Leela Sedaghat; Natalia O Glebova; Tomohiro Kurosaki; Solomon H Snyder
Journal:  Nat Cell Biol       Date:  2003-11-09       Impact factor: 28.824

7.  Reovirus-induced apoptosis requires both death receptor- and mitochondrial-mediated caspase-dependent pathways of cell death.

Authors:  D J Kominsky; R J Bickel; K L Tyler
Journal:  Cell Death Differ       Date:  2002-09       Impact factor: 15.828

8.  Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins.

Authors:  Man-Seong Park; Megan L Shaw; Jorge Muñoz-Jordan; Jerome F Cros; Takaaki Nakaya; Nicole Bouvier; Peter Palese; Adolfo García-Sastre; Christopher F Basler
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Lyssavirus matrix protein induces apoptosis by a TRAIL-dependent mechanism involving caspase-8 activation.

Authors:  Raïd Kassis; Florence Larrous; Jérôme Estaquier; Hervé Bourhy
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Role of fusion protein cleavage site in the virulence of Newcastle disease virus.

Authors:  Aruna Panda; Zhuhui Huang; Subbiah Elankumaran; Daniel D Rockemann; Siba K Samal
Journal:  Microb Pathog       Date:  2004-01       Impact factor: 3.738

View more
  78 in total

1.  Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma.

Authors:  Chun-Xiao Zhang; Long-Wei Ye; Ying Liu; Xiao-Ya Xu; Dan-Rui Li; Yan-Qing Yang; Lu-Lu Sun; Jie Yuan
Journal:  Tumour Biol       Date:  2015-04-16

2.  Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions.

Authors:  Nicole B Glennon; Omar Jabado; Michael K Lo; Megan L Shaw
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

3.  Cell-type-specific innate immune response to oncolytic Newcastle disease virus.

Authors:  Moanaro Biswas; Sandeep R P Kumar; Adria Allen; Wang Yong; Ramadevi Nimmanapalli; Siba K Samal; Subbiah Elankumaran
Journal:  Viral Immunol       Date:  2012-07-18       Impact factor: 2.257

Review 4.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

5.  Antitumor and immunostimulatory activities of a genotype V recombinant attenuated veterinary Newcastle disease virus vaccine.

Authors:  Oscar Antonio Ortega-Rivera; J Luis Quintanar; Susana Del Toro-Arreola; Ángel G Alpuche-Solis; Mayra J Esparza-Araiza; Eva Salinas
Journal:  Oncol Lett       Date:  2017-11-09       Impact factor: 2.967

6.  Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.

Authors:  Sara Cuadrado-Castano; Juan Ayllon; Mena Mansour; Janis de la Iglesia-Vicente; Stefan Jordan; Shashank Tripathi; Adolfo García-Sastre; Enrique Villar
Journal:  Mol Cancer Ther       Date:  2015-03-11       Impact factor: 6.261

7.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

8.  Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India.

Authors:  U Kumar; S Kumar
Journal:  Cancer Gene Ther       Date:  2015-08-07       Impact factor: 5.987

9.  Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy.

Authors:  Raghunath Shobana; Siba K Samal; Subbiah Elankumaran
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

Review 10.  The therapeutic effect of death: Newcastle disease virus and its antitumor potential.

Authors:  Sara Cuadrado-Castano; Maria T Sanchez-Aparicio; Adolfo García-Sastre; Enrique Villar
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.